Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver-Kidney treatment response under review

NCT ID NCT06161766

Knowledge-focused Sponsor: University Hospital Freiburg Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from University Hospital Freiburg looked back at 490 patients with liver cirrhosis and signs of chronic kidney disease who were treated for hepatorenal syndrome. Researchers compared how well patients with and without pre-existing kidney disease responded to vasoactive drugs (terlipressin or noradrenalin) plus albumin. The goal was to understand treatment outcomes and help guide future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
terlipressin or noradrenalin plus albumin
What this could lead to
If successful, this could help doctors better identify which patients with liver and kidney problems are most likely to benefit from vasoactive treatment.
What could go wrong
This is a retrospective study, meaning it looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

490 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with confirmed liver cirrhosis with ascites due to portal hypertension and 3) Clinical suspicion of HRS-AKI or HRS-AKI-like syndrome are included in this study. HRS-AKI-like syndrome is defined as typical features of HRS but wuth pre-existing chronic kidney disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with cirrhosis confirmed by histology or liver stiffness or with unequivocal signs in ultrasound, endoscopy and/or blood tests hospitalized between 1st of January 2018 and 31st of December 2022. * Evidence of ascites due to portal hypertension * Clinical suspicion of HRS-AKI or HRS-AKI-like syndrome (in case of previously diagnosed CKD) * Pre-existing data on kidney function (SCr and eGFR) minimum 3 months prior to admission in a stable situation * Dip stick urine test results (screening for proteinuria and hematuria) before initiation of AKI-treatment * Vasoactive treatment for the management of HRS-AKI, as defined by the administration of terlipressin or noradrenalin plus albumin * Age ≥ 18 years old Exclusion Criteria: * Uncontrolled shock * Patients with cardiac cirrhosis as defined by the development of cirrhosis in a patient with chronic heart failure due to a primary cardiac disease (ischemic cardiomyopathy, hypertensive cardiomyopathy, etc.) * Patients with hepatocellular carcinoma BCLC C or D * Patients receiving renal replacement therapy at baseline

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome cirrhosis of liver hepatorenal syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases Hepato-renal syndrome Liver cirrhosis

Contacts and locations

Locations

  • University Hospital Münster

    Münster, Germany

  • University Medical Center Freiburg

    Freiburg im Breisgau, Germany

  • University Medical Center Mainz

    Mainz, Germany

  • University Medical center Jena

    Jena, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.